WELLESLEY HILLS, Mass., Oct. 16 /PRNewswire-FirstCall/ -- MacroChem (OTC Bulletin Board: MACM) will participate in the PIPEs Conference 2007 to be held at the Hilton New York on October 18 and 19. The company will have an exhibit table, located outside the Sutton Room, throughout each day of the conference. MacroChem's President and Chief Executive Officer, Robert J. DeLuccia, will provide a company overview, including discussion about MacroChem's lead product, EcoNail(R), which is currently in a fully enrolled Phase 2 clinical trial. DeLuccia will also discuss MacroChem's newly acquired rights to pexiganan, a novel, topical anti-infective drug for treatment of diabetic foot infection (DFI), and its recent preferred stock conversion and private placement.
The PIPEs Conference will be a mix of education and networking with active investors in the small cap equity market. Two full days of programming will provide insight on industry developments from experts in the field, as well as networking opportunities with institutional investors, investment bankers, corporate attorneys, company executives, financial analysts, and media representatives from around the globe.
MacroChem Corporation is a specialty pharmaceutical company that
develops and seeks to commercialize pharmaceutical products. Our lead
product candidate is EcoNail, a topically applied SEPA-based econazole
lacquer for the treatment of onychomycosis, a condition commonly known as
nail fungus. We recently acquired exclusive worldwide license rights to
pexiganan, a novel topical anti-infective for the treatment of diabetic
foot infection, which has already completed two Phase 3 trials. Our other
clinical stage product candidate, Opterone(R), is a topically applied
SEPA-based testosterone cream designed to treat male hypogonadism. Our
pipeline of clinical-stage and early-stage product candidates is based on
our SEPA(R), MacroDerm(TM) and DermaPass(TM) drug delivery techno
|SOURCE MacroChem Corporation|
Copyright©2007 PR Newswire.
All rights reserved